Immune Responses in Type 1 Diabetes

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: 20 July 2025 | Viewed by 1300

Special Issue Editors


E-Mail Website
Guest Editor
Translational Research Program, Benaroya Research Institute, Seattle, WA 98101, USA
Interests: human type 1 diabetes; autoimmunity; T cell immunity; target tissue

E-Mail Website
Guest Editor
Department of Medicine, UMass Chan Medical School, Worcester, MA 01605, USA
Interests: human type 1 diabetes; autoimmunity; T cell responses

Special Issue Information

Dear Colleagues,

Type 1 diabetes (T1D) represents an archetypical polygenic autoimmune disease that renders patients insulin-dependent through the depletion of functional pancreatic beta cells via a combination of direct killing, apoptosis, and cellular dysfunction. The management of the disease requires a precisely administered insulin regimen to avoid ketoacidosis due to acute, severe hyperglycemia and long-term complications due to the accumulated effects of glucose excursions while avoiding hypoglycemia. The risk for the development of T1D can be predicted through the occurrence of biochemically defined islet autoantibodies. Furthermore, the genetic risk for the disease is dominated by the HLA class II locus, along with HLA class I and a broad number of immune response-related genes with more modest effect sizes. Early histological studies and more recent and elegant studies of human pancreatic tissue from organ donors have consistently revealed the HLA class I expression and document infiltration of the islets by multiple types of immune cells, including CD8+ and CD4+ T cells, gamma delta T cells, myeloid cells, NK cells, B cells, and CD11c+ antigen presenting cells. The role that these varied immune cell populations play in the disease process remains an important area of active investigation. In spite of the recent efforts, only limited information exists regarding the antigen and epitope specificity of islet-infiltrating T cells, but the existing literature confirms the presence of both autoreactive and bystander T cells. Accumulating studies also support the existence of an ongoing dialog between immune cells and pancreatic beta cells, which may include both disease-promoting and disease-restraining effects. Exploring this complex landscape offers the opportunity to unravel underlying causes of disease, sources of heterogeneity, and avenues for effective intervention.

Therefore, the goal of this Special Issue, entitled “Immune Responses in Type 1 Diabetes", is to provide a broad overview of the contribution of various immune cell subsets to disease development and etiology, including knowledge gained through the study of human subjects and animal models of the disease. This Special Issue aims to provide insights about the dialog between immune cells and pancreatic islets, including mechanisms that promote or restrain diabetes progression. Original research using conventional (e.g., immunohistochemistry, cell culture, flow cytometry) and more advanced methods of tissue and cellular characterization (e.g., scRNA-Seq and scATAC-Seq) are invited, as are well-balanced review articles. We welcome your contributions to this important Special Issue.

Dr. Eddie A. James
Dr. Sally C. Kent
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • type 1 diabetes
  • insulitis
  • immune response

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

11 pages, 340 KiB  
Review
Current and Emerging Assays for Measuring Human T-Cell Responses Against Beta-Cell Antigens in Type 1 Diabetes
by Ting-Chen Lin, Matthew Lacorcia and Stuart I. Mannering
Biomolecules 2025, 15(3), 384; https://doi.org/10.3390/biom15030384 - 6 Mar 2025
Viewed by 121
Abstract
Type 1 diabetes (T1D) is an autoimmune disease caused by T-cell mediated destruction of the pancreatic insulin-producing beta cells. Currently, the development of autoantibodies is the only measure of beta-cell autoimmunity used in the clinic. Despite T-cells’ well-accepted role in the autoimmune pathogenesis [...] Read more.
Type 1 diabetes (T1D) is an autoimmune disease caused by T-cell mediated destruction of the pancreatic insulin-producing beta cells. Currently, the development of autoantibodies is the only measure of beta-cell autoimmunity used in the clinic. Despite T-cells’ well-accepted role in the autoimmune pathogenesis of human T1D, autoimmune T-cell responses against beta cells remain very difficult to measure. An assay capable of measuring beta-cell antigen-specific T-cell responses has been a long-sought goal. Such an assay would facilitate the direct monitoring of T1D-associated T-cell responses facilitating, earlier diagnosis and rapid evaluation of candidate immune therapies in clinical trials. In addition, a simple and robust assay for beta-cell antigen-specific T-cell responses would be a powerful tool for dissecting the autoimmune pathogenesis of human T1D. Here, we review the challenges associated with measuring beta-cell antigen-specific T-cell responses, the current assays which are used to achieve this and, finally, we discuss BASTA, a promising emerging assay for measuring human beta-cell antigen-specific CD4+ T-cell responses. Full article
(This article belongs to the Special Issue Immune Responses in Type 1 Diabetes)
Show Figures

Figure 1

18 pages, 2516 KiB  
Review
Dia-B-Ties: B Cells in the Islet–Immune-Cell Interface in T1D
by Brandon K. Hilliard, Jessica E. Prendergast and Mia J. Smith
Biomolecules 2025, 15(3), 332; https://doi.org/10.3390/biom15030332 - 25 Feb 2025
Viewed by 376
Abstract
Type 1 diabetes (T1D) is an autoimmune disease that affects an estimated 30 million people worldwide and results in a lifelong dependency of exogenous insulin treatments. While T1D is characterized by T-cell driven-destruction of the insulin-secreting β cells, B lymphocytes play a key [...] Read more.
Type 1 diabetes (T1D) is an autoimmune disease that affects an estimated 30 million people worldwide and results in a lifelong dependency of exogenous insulin treatments. While T1D is characterized by T-cell driven-destruction of the insulin-secreting β cells, B lymphocytes play a key role in the islet–immune interface. B cells are an essential intermediary between islet cells and other immune-cell populations. Through antigen presentation, cytokine secretion, and antibody production, B cells play a role in activating autoreactive islet-specific T cells, thus potentiating pancreatic inflammation in the early stages of T1D. Despite this, their role in disease development remains an understudied feature of T1D with significant therapeutic potential. Herein, we will discuss the current knowledge of the islet–immune-cell interface within T1D through the lens of B lymphocytes. We will also consider knowledge gaps that may be limiting further therapeutic opportunities. Full article
(This article belongs to the Special Issue Immune Responses in Type 1 Diabetes)
Show Figures

Figure 1

Back to TopTop